At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PBLA Panbela Therapeutics, Inc.
Closed 11-22 16:00:00 EST Delay
Panbela Provides Business Update and Reports Q3 2024 Financial Results
BRIEF-Panbela Therapeutics Announces Third Independent Safety Review Of Phase 3 Aspire Clinical Trial DSMB Recommended Continuation With No Trial Modification
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 Aspire Clinical Trial Dsmb Recommended Continuation With No Trial Modification
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.